Publications by authors named "Mio Matsubara"

Claim this Profile
C
Comparison of surgical outcomes between iStent and iStent inject W with ≥2 years of follow-up: a propensity score matching analysis.
Hiroshi Kasai, Tadao Ooka, Chio Kuleshov, Yuka Hasebe, Mio Matsubara

Jpn J Ophthalmol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genetic characteristics of simple central serous chorioretinopathy according to age.
Taiyo Shijo, Ayumi Fukui, Yoichi Sakurada, Nobuhiro Terao, Seigo Yoneyama, Mio Matsubara

Ophthalmic Genet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.
Misa Kimura, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda

Pharmaceuticals (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCIDENCE AND CHARACTERISTICS OF NEOVASCULAR AGE-RELATED MACULAR WITH OVER A 12-MONTH REMISSION AFTER THREE MONTHLY AFLIBERCEPT ADMINISTRATION: 60 Months Results of a Pro Re Nata Regimen.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Seigo Yoneyama

Retina· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yumi Kotoda, Yuka Kasai

Jpn J Ophthalmol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda

Pharmaceuticals (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DISTINCT CHARACTERISTICS OF SIMPLE VERSUS COMPLEX CENTRAL SEROUS CHORIORETINOPATHY.
Seigo Yoneyama, Ayumi Fukui, Yoichi Sakurada, Nobuhiro Terao, Taiyo Shijo, Mio Matsubara

Retina· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mid-Term Results of Ab Interno Trabeculectomy among Japanese Glaucoma Patients.
Kazuyoshi Kitamura, Yoshiko Fukuda, Yuka Hasebe, Mio Matsubara, Kenji Kashiwagi

J Clin Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Measurements Are Necessary for Evaluating Accurate Diurnal Rhythm Using a Self-Intraocular Pressure Measurement Device.
Yumi Shigemoto, Yuka Hasebe, Kazuyoshi Kitamura, Yoshiko Fukuda, Masako Sakamoto, Mio Matsubara

J Clin Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of intermediate age-related macular degeneration with hyperreflective foci.
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara

Sci Rep· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct characteristics of central serous chorioretinopathy according to gender.
Seigo Yoneyama, Ayumi Fukui, Yoichi Sakurada, Nobuhiro Terao, Taiyo Shijo, Mio Matsubara

Sci Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Yumi Shigemoto, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Ravi Parikh

Medicine (Baltimore)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy.
Wataru Kikushima, Yoichi Sakurada, Seigo Yoneyama, Atsushi Sugiyama, Mio Matsubara

Photodiagnosis Photodyn Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yuka Hasebe, Atsushi Sugiyama

Biomedicines· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity.
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara

J Clin Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration.
Taiyo Shijo, Yoichi Sakurada, Yoshiko Fukuda, Seigo Yoneyama, Atsushi Sugiyama, Mio Matsubara

Int Ophthalmol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.
Mio Matsubara, Yoichi Sakurada, Atsushi Sugiyama, Yoshiko Fukuda, Ravi Parikh

PLoS One· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration.
Taiyo Shijo, Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara

Pharmaceuticals (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Title: Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy.
Yoshiko Fukuda, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara

J Clin Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
Kikushima Wataru, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda

PLoS One· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Seigo Yoneyama, Yoichi Sakurada, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara

Sci Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
Wataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudodrusen pattern and development of late age-related macular degeneration in the fellow eye of the unilateral case.
Yoichi Sakurada, Atsushi Sugiyama, Wataru Kikushima, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara

Jpn J Ophthalmol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration.
Yoshiko Fukuda, Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara

Sci Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision.
Kenji Kashiwagi, Mio Matsubara

J Ophthalmol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis